NYSE: BIO
- Last Close 353.03
- Sector Healthcare
- Industry Medical Devices
- Investment Style Mid Blend
- Day Range 351.96 – 358.77
- Year Range 344.63 – 509.62
- Market Cap 10.2648 Bil
- Volume / Avg 104,276.0 / 189,761.8
- Price / Sales 3.77
- Price / Book 1.22
- Forward Div Yield —
- Trailing Div Yield —
Morningstar‘s Stock Analysis BIO
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
Capital Allocation
INVESTOR
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile BIO
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas, Europe and Africa , and Asia-Pacific. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Related Articles BIO
Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of BIO’s competitive advantage.
Bio-Rad Laboratories Inc Class A
XNYS: BIO
| Becton Dickinson & Co
XNYS: BDX
| Thermo Fisher Scientific Inc
XNYS: TMO
| Merck KGaA
XETR: MRK
| |
Price
| 353.03 | 265.20 | 502.79 | 159.20 |
Currency
| USD | USD | USD | EUR |
Change
| −$4.27 (1.20%) | +$0.16 (0.06%) | +$1.20 (0.24%) | −$1.30 (0.81%) |
Market Cap
| 10.26 Bil | 76.94 Bil | 194.05 Bil | 69.22 Bil |
Industry
| Medical Devices | Medical Instruments & Supplies | Diagnostics & Research | Drug Manufacturers - Specialty & Generic |
Sector
|
Healthcare
|
Healthcare
|
Healthcare
|
Healthcare
|
* Trading data in this section is delayed by at least 15 minutes.
FAQs for Bio-Rad Laboratories Inc Class A Stock
No. BIO does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
BIO’s market cap is 10.26 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
BIO’s stock style is Mid Core.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
BIO’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare BIO’s historical performance against its industry peers and the overall market.